



## Herbal Drugs as Anti-Tuberculosis Agents

*Mehta Shashidhar<sup>1\*</sup>, Mehta S. Sandhya<sup>2</sup>, Patyal Pankaj<sup>3</sup>, Bhatnagar Suhasini<sup>1</sup>*

<sup>1</sup> Department of Biochemistry, Mewar University, Chittorgarh, Rajasthan, India

<sup>2</sup> Department of Microbiology, LHMC & SK Hospital, New Delhi, India

<sup>3</sup> Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, United States

### Abstract

Tuberculosis is the main cause of morbidity in modern era and came to existence many decades ago and has emerged as pandemic disease. The use of allopathic medicine in complex disease like tuberculosis is associated with the problem of cross resistance and herbal drugs have proven to be most effective in this context. The exploration of therapies for the successful attenuation of the morbid condition associated with tuberculosis is the need of the day.

### Introduction

Tuberculosis caused the most widespread public concern in the 19th and early 20th centuries as an endemic disease of the urban poor. According to World Health Organisation (WHO), Tuberculosis, or TB, is an infectious bacterial disease caused by *Mycobacterium tuberculosis*, which most commonly affects the lungs. It is transmitted from person to person via droplets from the throat and lungs of people with the active respiratory disease.

24<sup>th</sup> March is celebrated as the world TB day to make the entire world remind about the major pandemic threat that is a mandate issue needing to be resolved at a fast pace. Tuberculosis (TB) is a disease of poverty, and a major cause of morbidity and mortality occurring in developing countries. Tuberculosis (TB) is a bacterial infection caused mainly by *Mycobacterium tuberculosis* (MTB). The pathophysiology of TB has been studied extensively from the last decades.

Scientist from London stated that discovery of new drug especially from plant origin is the need of the day. These new drugs are used for attenuation of complexity of current therapy, improve treatment of MDR TB and control of latent TB.

The WHO intends to integrate traditional medicine into National Health systems (NHS) globally. This is an opportunity for building safe, affordable and effective NHS especially for Third world countries, rich in both medicinal plant resources and traditional medicine knowledge. It is the time for Governments to found research into holistic health models instead of squandering more billions on 'health genomics', which will increase intervention and iatrogenic damages to health.

Anti-TB drugs consist of two groups: essential or first line drugs, which are usually used for the treatment of TB patients with susceptible *Mycobacterium tuberculosis*; and reserve or second-line anti-TB drugs used for the treatment of multidrug-resistant TB (MDR-TB). Second-line drugs have many more adverse effects than the first-line anti-TB drugs.

The human being appears to be affected with more diseases than any other animal species. Among various morbidities affecting human, respiratory diseases are more present. Tuberculosis is a disease of antiquities which is thought to have evolved sometime between the seventh and sixth millennia B.C. This spreading disease TB was diagnosed in modern medicine at the beginning of 19th century after the identification of mycobacterium by Robert Koch. But our Indian Systems of Medicine started treating this disease from 5000 BC by use of herbal drugs. TB was diagnosed in Ayurveda and Siddha systems of medicine.

### **TB Pathophysiology**

*M. tuberculosis* requires the presence of oxygen to grow. It does not require any bacteriological stain due to high lipid content in its wall, and thus is never considered as Gram-positive nor Gram-negative; hence Ziehl-Neelsen staining, or acid-fast staining, is used. The mycobacteria do not seem to fit the Gram-positive category from an empirical standpoint (i.e., they do not retain the crystal violet stain), they are classified as acid-fast Gram-positive bacteria due to their lack of an outer cell membrane. *M. tuberculosis* replicates every 15–20 hours, which is extremely slow compared to other bacteria, which tend to have division times measured in minutes. Specifically, *M. tuberculosis* blocks the bridging molecule, early endosomal autoantigen 1 (EEA1); however, this blockade does not prevent fusion of vesicles filled with nutrients. Consequently, the bacteria multiply unchecked within the macrophage. The bacteria also carry the UreC gene, which prevents acidification of the phagosome. The bacteria also evade macrophage-killing by causing the neutralization of reactive nitrogen intermediates.

### **Herbal Drugs: Need of the day**

The current therapy for TB includes antibiotics such as rifampicin, ethambutol, isoniazid and pyrazinamide, but the emergence of a problem of multiple drug resistant (MDR) and (XDR) strains of mycobacterium is very common with anti TB drugs. The presence of “cross resistance” causes no single drug or combination therapy was able to control TB fully and such drug resistance is developed only against purified chemical compounds. Any single purified compound will produce resistance in pathogens. The Mycobacteriae are self-equipped to digest the drug by modifying their receptor structure according to the chemical structure of the drug. Thus the Mycobacteriae slowly adapt and develop resistance against modern drugs. Herbal drugs, whether extract or decoction used against any pathogen will not cause the problem of drug resistance. Hence

an effective and appropriate drug therapy as an anti tuberculosis drug need to be discovered which will solve the problem of cross resistance as well as drug resistance.

### Adverse effects associated with anti TB therapy

Hepatitis----- Isoniazid

Pain, nausea, vomiting, hepatitis, thrombocytopenia----- Rifampicin

Convulsions, Dizziness, headache, depression, psychotic reactions-----Cycloserine

Arthralgia, hepatitis----- Pyrazinamide

Vestibular and auditory nerve damage, renal damage----- Streptomycin

Skin rash, Exfoliative dermatitis----- Thioacetazone

Vertigo, auditory nerve damage, nephrotoxicity----- Kanamycin

Diarrhoea, abdominal pain, hepatotoxicity----- Ethionamide

Eye problems, neuritis ----- Ethambutol

### Glance of herbal anti-tubercular drugs

| Botanical Name              | Family        | Chemical Constituents  | Activity   | Ayurvedic Name |
|-----------------------------|---------------|--|--|----------------|
| <i>Allium cepa</i>          | Liliaceae     | allylpropylsulfide, sulphurcontaining compounds, including allicin, alliin, flavonoids; phenolic acids and sterols | Antibiotic, antibacterial, antisclerotic, anticoagulant  | Palaandu       |
| <i>Aloe vera</i>            | Liliaceae     | aloin  | Purgative  | Ghritkumaarika |
| <i>Trichosanthes dioica</i> | Cucurbitaceae | nicotinic acid, riboflavin, vitamin C, thiamine, 5-hydroxytryptamine   | Cathartic, febrifuge   | Patola         |
| <i>Prunus armeniaca</i>     | Rosaceae      | Protocatechuic, p-coumaric, Ferulic acid   | antiasthmatic  | Peetaalu       |
| <i>Ocimum sanctum</i>       | Labiatae      | apigenin, orientin, luteolin, apigenin-7-O-glucuronide   | Carminative, stomachic, antispasmodic, antiasthmatic, antirheumatic, expectorant, hepatoprotective, antiperiodic | Tulsi          |

|                                  |                      |   |  |            |
|----------------------------------|----------------------|---|--|------------|
| <i>Canscora decussate</i>        | <i>Gentianaceae</i>  | $\beta$ -amyrin, friedelin, genianine mangiferin, Xanthones   | Anticonvulsant, CNS depressant, antiinflammatory, hepatoprotective | Daakuni    |
| <i>Clavija procera</i>           | Theophrastaceae      | -   | Oleanane triterpenoid (aegicerin)                                  | -          |
| <i>Cryptocarya latifolia</i>     | Lauraceae            | -   | Coumarins  | -          |
| <i>Colebrookea oppositifolia</i> | Lamiaceae            | Flavonoids  | Antiinflammatory   | Binda      |
| <i>Kalanchoe integra</i>         | Crassulaceae         | Triterpenoids-friedelin, taraxerol and glutinol and a mixture of long chain hydrocarbons  | Hypotensive, antiarrhythmic  | Parnabija  |
| <i>Mallotus philippensis</i>     | <i>Euphorbiaceae</i> | Phloroglucinol derivatives; rottlerin, isorottlerin, iso allorottlerin  | Purgative, anthelmintic, styptic                                   | Kampillaka |
| <i>Kalanchoe integra</i>         | Crassulaceae         | Triterpenoids-friedelin, taraxerol and glutinol and a mixture of long chain hydrocarbons  | Hypotensive, antiarrhythmic  | Parnabija  |
| <i>Flacourtia ramontchii</i>     | Flacourtiaceae       | Phenolic glucoside ester, (-)-flacourtin, ramontoside, $\beta$ -sitosterol and its $\beta$ -D-glucopyranoside                   | Anticholinergic  | Vikankata  |
| <i>Leysera gnaphalodes</i>       | <i>Asteraceae</i>    | Non-cytotoxic triterpenoids oleanolic   | -  | -          |
| <i>Morinda citrifolia,</i>       | Rubiaceae            | Anthraquinonesalizarin and its glycosides, nordamnacanthol. Ursolic acid and $\beta$ -sitosterol. asperuloside and caproic acid | Antileucorrhoeic, antidysenteric emmenagogue                       | Ashoka     |

## Conclusion

The side effects associated with the allopathic drugs have remarkably necessitated the need of herbal drugs. In this review, authors have tried to make a complete description of all the antitubercular drugs around the globe. The various constituents present in plants make them as an effective antitubercular drug. The discovery of new drugs has finally begun to emerge, the standard of care for tuberculosis might become possible soon, and the framework for classification of drug-resistant cases will need to be explored. Although

the prevalence of TB in the society exists from large decades, still research needs to be explored for the benefit of the society.

## References

1. Sam Burcher and Mae-Wan Ho, 1996. *Prac. Global strategy for traditional medicine research*: 142-144
2. Zink A, Sola C, Reischl U, Grabner W, Rastogi N, Wolf H, Nerlich A (2003). "Characterization of Mycobacterium tuberculosis Complex DNAs from Egyptian Mummies by Spoligotyping". *J Clin Microbiol* 41 (1): 359–67. doi:10.1128/JCM.41.1.359-367.2003. PMC 149558. PMID 12517873.
3. Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. "Occurrence of side effects from antituberculosis drugs in urban nepalese population under dots treatment". *Kathmandu university journal of science, engineering and technology* 2005; 1(1).
4. Abbruzzese, M.R., Delaha, E.C., Garagusi, V.F., 1987. Absence of antimyco bacterial synergism between garlic extract and antituberculosis drugs. *Diag. Microbiol. Infect. Dis.*; 8(2): 79-85.
5. Gabbrielli, G., Loggini, F., Cioni, P.L., Giannaccini, B., Mancuso, E. 1988. Activity of lavandino essential oil against non-tubercular opportunistic rapid grown mycobacteria. *Pharmacol. Res. Commun.*; 20 Suppl. 5:37-40.
6. Ma, T.S. and Roper, R., 1968. Microchemical investigation of medicinal plants, I. The antitubercular principle in *Prunus mume* and *Schizandra chinensis*. *Mikrochim. Acta.*; 167-181.
7. Ghosal, S. and Chaudhuri, R.K., 1975. chemical constituents of Gentianaceae XVI; antitubercular activity of xanthones of *Canscora decussate* Schult. *J. Pharm. Sci.*; 64: 888-889.
8. Glasby, S., 1976. *Encyclopedia of Antibiotics*, Wiley, London. Pp. 352.
9. Gupta, O.P., Amarnath, Gupta, S.C. and Srivastava, T.N. 1980. Preparation of semi- synthetic analogues of Piper amides and their antitubercular activity. *Bull. Med. Ethnobot. Res.*; 1(1): 99-106.
10. Ghosh S, Malik SK, Gupta A, Chaudhary R. "A prospective, observational cohort study to elicit adverse effects of anti-tuberculosis drugs among patient treated for active tuberculosis". *The Pharma Research (T. Ph. Res.)* 2010; 3: 10-16.
11. Nahar BL, Mosharraf Hossain AKM, Islam MM and Saha DR. "A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period". *Bangladesh J Pharmacol* 2006; 1: 51-57.
12. Sehlapelo BM, Drewes SE, Scott-Shaw R. "A 6-substituted 5,6-dihydro- $\alpha$ -pyrone from two species of *Cryptocarya*". *The International Journal of Plant Biochemistry* 1994; 37(3): 847-849.

13. Bapela MJ, Lall N, Isaza-Martinez JH, Regnier T, Meyer JJM. "Variation in the content of naphthoquinones in seeds and seedlings of *Euclea natalensis*". South African Journal of Botany 2007; 73(4): 606-610.
14. Sobhy EA, Feky SS. "Chemical constituents and antimicrobial activity of *Helichrysum stoechas*". Asian journal of plant sciences 2007; 6(4): 692-695.
15. Koyama J. "Anti-Infective Quinone Derivatives of Recent Patents". Recent Patents on Anti-Infective Drug Discovery 2006; 1: 113-125.
16. Imelouane B, Amhamdi H, Wathelet JP, Ankit M, Khedid K, Bachiri A. "Chemical Composition and Antimicrobial Activity of Essential Oil of Thyme (*Thymus vulgaris*) from Eastern Morocco". International Journal of Agriculture and Biology 2009; 11(2):205-208.
17. Bamuamba K, Gammon DW, Meyers P, Dijoux- Franca MG. "Anti-mycobacterial activity of five plant species used as traditional medicines in the Western Cape Province (South Africa)". Journal of Ethnopharmacology 2008; 117(2-8):385-390.
18. Gandhi, N.R., Moll, A., Sturm, A.W. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet., 2006; 368(9547): 1575-1580.
19. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010; 375(9731): 2100-2109.
20. Diacon, A.H., Pym, A., Grobusch, M. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New Engl. J. Med., 2009; 360(23): 2397-2405.
21. Gler, M.T., Skripconoka. V., Garavito, E. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2012; 366(23): 2151-2160.